Page last updated: 2024-10-24

candesartan and Chronic Hepatitis C

candesartan has been researched along with Chronic Hepatitis C in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abd Alla, MD1
Eid, EMM1
Soliman, AIA1
Elhawary, MA1
Kilany, YF1
Abd-Almonaem, G1
Bayoumi, SS1
Moursy, MRA1
Al-Zaem, FAM1

Trials

1 trial available for candesartan and Chronic Hepatitis C

ArticleYear
PORTAL HYPERTENSION TREATMENT WITH CANDESARTAN PLUS PROPRANOLOL FOR NINE MONTHS RESTORES NORMAL PORTAL CIRCULATION HEMODYNAMIC PATTERN.
    Journal of the Egyptian Society of Parasitology, 2016, Volume: 46, Issue:3

    Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Drug Administration Schedule; Drug Ther

2016